Pharmidex attending the Global Business Accelerator visit to Switzerland
March 10, 2018

Pharmidex will be attending the Global Business Accelerator Program which is run by the Enterprise Europe Network and supported by Innovate UK.

The Enterprise Europe Network, supported by Innovate UK, are visiting Switzerland to focus on the pharmaceutical technology industry. The chosen companies will have the opportunity to meet pharmaceutical companies and key stakeholders based in Basel and attend ProcureCon Pharma in Zürich for the next three days


The Swiss pharmaceutical sector is a major employer with more than 40,000 people working directly for the industry. If the indirect work created through ancillary industries is included, as many as 172,000 jobs are related to the pharmaceutical industry. In addition, it accounts for up to a third of all Swiss exports, and the productivity of the industry is four times as high as that of the economy as a whole.


Three big clusters – the Lake Geneva area, the Basel region and Zürich-Zug-Lucerne – account for the lion’s share of the gross value added of the Swiss pharmaceutical industry and present many collabartive opputunities for UK companies. 


During the trip Pharmidex will also be attending ProcureCon Pharma, organised by Worldwide Business Research, will take place from 13 to 15 March 2018 in Zürich. Delegates will have the opportunity to join 200 senior procurement professionals from Merck, Astra Zeneca, Roche, Sanofi, Lonza and other world-leading pharmaceutical businesses over three days. 


We look forward to meeting you there.

June 8, 2026
Pharmidex is seeking an experienced and driven Principal / Senior Translational Pharmacologist to join our growing Translational Research team and lead innovative ophthalmology programmes. We're looking for a senior scientist with expertise in ophthalmology, ocular disease models, and translational pharmacology who is ready to make a real impact in a dynamic CRO environment. ✅ Competitive salary and benefits ✅ High-visibility scientific leadership role ✅ Opportunities to present at international conferences ✅ Direct impact on advancing innovative medicines toward the clinic
May 26, 2026
What started in 2002 with a small team and a handful of clients has grown into a global preclinical CRO trusted by more than 400 clients worldwide, including many leading pharmaceutical and biotechnology companies. Our commitment to delivering bespoke and standard study designs in a quick, expert, and cost-effective manner has allowed us to support more than 1,000 studies per year for multiple consecutive years, something we are incredibly proud of. Over the years, we have been fortunate to contribute data supporting numerous marketed drugs, numerous successful client acquisitions, and programmes successfully supporting patients. Most importantly, our success is a testament to the wider scientific community and the innovative ideas and projects our clients trust us to support every day. Thank you to every client, collaborator, colleague, and friend who has been part of our journey so far. We look forward to supporting the next generation of science and innovation for another 24 years.
May 20, 2026
We are delighted to announce the promotion of Dr. Martin Barrett to Chief Business Officer at Pharmidex . Martin brings more than 23 years of experience across the pharmaceutical and drug discovery sectors, combining deep scientific expertise with strategic commercial leadership. Throughout his career, he has played a key role in advancing translational science, building strategic partnerships and supporting innovative drug development programmes. In his new role, Martin will help drive Pharmidex’s continued growth, strengthen collaborations, and expand our capabilities across preclinical pharmacology, toxicology, translational science, and clinical development support. Congratulations to Martin on this well-deserved promotion. We look forward to the continued impact of his leadership across Pharmidex and the wider drug discovery community.
More Posts